Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Providing unparalleled analysis and insight of the deals and products
shaping the Health Care industry.
|
|
|
 |
Subscriber
Login |
|
|
Strategic Transactions delivers the most comprehensive deals data in
the industry,
including alliances, financings and M&As across biopharmaceuticals, devices,
diagnostics and tech transfers. Better yet, it’s the only database with
available, hyperlinked analysis from our award-winning editorial staff.
You'll receive:
- More than 24,000 deals from 1991 to the present
- Summaries of company, product and financial information, plus SEC &
contract filings
- Simple and sophisticated search that’s fully exportable
- Extensive cross-linking of deals, companies and commentary
- Regular e-newsletter includes new and updated deals
- Thoroughly fact-checked by a dedicated team of analysts
Benchmark competitors, evaluate comparable deals, gather authoritative data
for negotiations, and profile potential partners with Strategic Transactions.
Learn more!
|
 |
Inteleos offers the in-depth drug information you need to fully understand the value of a deal for a particular drug and be confident in your dealmaking decisions. |
|
Upgrade your Strategic Transactions
subscription to include the latest product pipeline data from Inteleos.
Learn more. |
|
|
|
|
|
|
 |
Subscriber
Login |
|
|
Inteleos features comprehensive data on more than 10,000 drugs and biologics,
complete with in-depth regulatory coverage, detailed development timelines and
competitor profiles. Inteleos is the premier business intelligence tool and offers intuitive indexing and search capabilities with flexible export options to fulfill your drug development research needs.
You'll receive:
- Track biologic and drug development from preclinical through approval and post-marketing studies
- Find information about new partners and stay up to date on competitor's activities
- In depth regulatory submission and approval filings with industry, conference and regulatory news from leading Elsevier sources
- Detailed clinical trial info
- Graphically dynamic analysis tools to view content from different perspectives
- Personalized alerts on content updates relevant to your portfolio
Inteleos is the most intuitive, flexible tool for drug pipeline, research, tracking and analysis.
Learn more! |
|
|
|
|
 |
Subscriber
Login |
|
|
Transaction Tracker is a snapshot of current pharmaceutical
dealmaking activity, featuring the most recent two months of data plus analysis
of the latest trends. It’s the most popular features of
Strategic Transactions
at an affordable price!
You'll receive:
- Dealmaking activity: A complete picture of the most recent two months of
transactions
- Dedicated homepage: A homepage exclusively for Transaction Tracker subscribers
that’s user-friendly and convenient
- Deal updates: Continual updates of earlier deals
- FREE weekly email: An available, FREE weekly email newsletter to alert
you to the hottest new activity
- Analysis & commentary: Selected trend analysis from
our dedicated
editorial team
- Profiles: In-depth profiles of all deal-active companies
Transaction Tracker is designed to help you stay on top of the fast-moving
dealmaking landscape and identify risks and opportunities for your business
across the industry.
Learn more! |
|
| To request further information on the Elsevier Business
Intelligence suite of database
products, please contact James DeFalco at (203) 838-4401 ext: 104 or via
email at: j.defalco@elsevier.com |
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
